Ratio of cyclin-dependent kinase 1 (CDK1) activity to CDK2 activity after ex vivo paclitaxel treatment predicts response to paclitaxel in human breast cancer

被引：0
|
作者：
Kim, S. J.
Taguchi, T.
Tamaki, Y.
Tsukamoto, F.
Akazawa, K.
Ueno, N. T.
Hortobagyi, G. N.
Nakayama, S.
Torikoshi, Y.
Gohda, K.
Ishihara, H.
Noguchi, S.
机构：
[1] Osaka Univ, Grad Sch Med, Osaka, Japan
[2] Osaka Koseinenkin Hosp, Osaka, Japan
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Sysmex Corp, Kobe, Hyogo, Japan
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：366S / 366S
页数：1
相关论文
共 50 条
  • [1] Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells
    Nakayama, Satoshi
    Torikoshi, Yasuhiro
    Takahashi, Takeshi
    Yoshida, Tomokazu
    Sudo, Tamotsu
    Matsushima, Tomoko
    Kawasaki, Yuko
    Katayama, Aya
    Gohda, Keigo
    Hortobagyi, Gabriel N.
    Noguchi, Shinzaburo
    Sakai, Toshiyuki
    Ishihara, Hideki
    Ueno, Naoto T.
    BREAST CANCER RESEARCH, 2009, 11 (01):
  • [2] Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells
    Satoshi Nakayama
    Yasuhiro Torikoshi
    Takeshi Takahashi
    Tomokazu Yoshida
    Tamotsu Sudo
    Tomoko Matsushima
    Yuko Kawasaki
    Aya Katayama
    Keigo Gohda
    Gabriel N Hortobagyi
    Shinzaburo Noguchi
    Toshiyuki Sakai
    Hideki Ishihara
    Naoto T Ueno
    Breast Cancer Research, 11
  • [3] Cyclin-dependent kinase 2 to 1 specific activity ratio predicts response to epirubicin and paclitaxel in human breast cancer
    Kim, S. J.
    Myoshi, Y.
    Taguchi, T.
    Tamaki, Y.
    Noguchi, S.
    Tsukamoto, F.
    Akazawa, K.
    Nakayama, S.
    Matsushima, T.
    Torikoshi, Y.
    Ishihara, H.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S90 - S90
  • [4] Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
    Kang, Jian
    Sergio, C. Marcelo
    Sutherland, Robert L.
    Musgrove, Elizabeth A.
    BMC CANCER, 2014, 14
  • [5] Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
    Jian Kang
    C Marcelo Sergio
    Robert L Sutherland
    Elizabeth A Musgrove
    BMC Cancer, 14
  • [6] An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)
    Liu, Xuanyou
    Wu, Hao
    Liu, Zhenguo
    CANCERS, 2022, 14 (11)
  • [7] Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers
    Kim, S. J.
    Nakayama, S.
    Shimazu, K.
    Tamaki, Y.
    Akazawa, K.
    Tsukamoto, F.
    Torikoshi, Y.
    Matsushima, T.
    Shibayama, M.
    Ishihara, H.
    Noguchi, S.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 891 - U3
  • [8] Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
    Shazia Sofi
    Umar Mehraj
    Hina Qayoom
    Shariqa Aisha
    Abdullah Almilaibary
    Mustfa Alkhanani
    Manzoor Ahmad Mir
    Medical Oncology, 39
  • [9] Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
    Sofi, Shazia
    Mehraj, Umar
    Qayoom, Hina
    Aisha, Shariqa
    Almilaibary, Abdullah
    Alkhanani, Mustfa
    Mir, Manzoor Ahmad
    MEDICAL ONCOLOGY, 2022, 39 (09)
  • [10] Transforming growth factor β targeted inactivation of cyclin E:cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity
    Nagahara, H
    Ezhevsky, SA
    Vocero-Akbani, AM
    Kaldis, P
    Solomon, MJ
    Dowdy, SF
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) : 14961 - 14966
12345